Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Shares Purchased by Samsara BioCapital LLC

Samsara BioCapital LLC lifted its stake in shares of Aclaris Therapeutics, Inc. (NASDAQ:ACRS - Free Report) by 242.6% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 2,385,060 shares of the biotechnology company's stock after acquiring an additional 1,688,889 shares during the quarter. Aclaris Therapeutics makes up approximately 0.8% of Samsara BioCapital LLC's holdings, making the stock its 22nd biggest holding. Samsara BioCapital LLC owned about 3.34% of Aclaris Therapeutics worth $5,915,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also bought and sold shares of the company. ExodusPoint Capital Management LP purchased a new stake in Aclaris Therapeutics during the 4th quarter worth approximately $26,000. Invesco Ltd. purchased a new stake in Aclaris Therapeutics in the 4th quarter worth $28,000. Commonwealth Equity Services LLC acquired a new position in shares of Aclaris Therapeutics during the 4th quarter worth about $36,000. Alpine Global Management LLC purchased a new stake in Aclaris Therapeutics during the 4th quarter worth approximately $38,000. Finally, Charles Schwab Investment Management Inc. purchased a new position in shares of Aclaris Therapeutics in the fourth quarter valued at approximately $82,000. 98.34% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of brokerages have recently commented on ACRS. StockNews.com cut shares of Aclaris Therapeutics from a "hold" rating to a "sell" rating in a research report on Saturday, February 8th. Cantor Fitzgerald initiated coverage on Aclaris Therapeutics in a report on Tuesday, March 18th. They set an "overweight" rating on the stock. Finally, Scotiabank assumed coverage on Aclaris Therapeutics in a report on Friday, March 7th. They issued a "sector outperform" rating and a $15.00 price target for the company. One investment analyst has rated the stock with a sell rating, seven have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $11.67.

Aclaris Therapeutics Trading Down 7.3 %

ACRS traded down $0.11 on Monday, hitting $1.34. The company had a trading volume of 130,073 shares, compared to its average volume of 1,181,913. The firm has a market cap of $144.56 million, a P/E ratio of -2.57 and a beta of 0.42. Aclaris Therapeutics, Inc. has a 1 year low of $0.95 and a 1 year high of $5.17. The company's fifty day moving average price is $1.48 and its 200 day moving average price is $2.25.

Aclaris Therapeutics Company Profile

Aclaris Therapeutics, Inc a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases.